| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC23772 | CMLD-2 | A novel small molecule disruptor of HuR-mRNA interaction with Ki of 350 nM. |
|
| DC11632 | Cardioprotectant | A novel small molecule inducer of heme oxygenase-1 that protect human iPSC-derived cardiomyocytes from oxidative stress. |
|
| DC25072 | Deltasonamide 1 | A novel small molecule inhibitor of PDE6δ/KRas interaction with Kd of 203 pM. |
|
| DC11817 | Compound L | A novel small molecule inhibitor of the DNA repair protein Ku70/80, disrupts of Ku70/80-DNA interaction with IC50 of 3.5 uM in EMSA assay. |
|
| DC21679 | Spindlactone A | A novel small molecule inhibitor of transforming acidic coiled-coil-containing protein 3 (TACC3) that selectively inhibits the nucleation of centrosome microtubules in ovarian cancer cells. |
|
| DC21680 | Spindlactone B | A novel small molecule inhibitor of transforming acidic coiled-coil-containing protein 3 (TACC3) that selectively inhibits the nucleation of centrosome microtubules in ovarian cancer cells. |
|
| DC22764 | CS-11 | A novel small molecule inhibitor that inhibits PP2A and β-catenin interaction by selectively engaging PR55α binding site (Kd=45 pM). |
|
| DC22879 | YK-3-237 | A novel small molecule sirtuin-1 (SIRT1) activator that reduces acetylation of mutant 53 and exhibits anti-proliferative effects against TNBC cells carrying mutant p53. |
|
| DC21330 | MM-206 | A novel small molecule STAT3 inhibitor that inhibits STAT3 DNA binding activity with IC50 of 1.16 uM, binds to the STAT3 coiled-coil domain (CCD). |
|
| DC20389 | GATA4 activator 7 | A novel small molecule that activates GATA4/NKX2-5 transcriptional synergy with EC50 of 7 uM in cell reporter assay. . |
|
| DC21039 | GATA4-IN-3 Featured | A novel small molecule that inhibits GATA4/NKX2-5 transcriptional synergy with IC50 of 3 uM, with no activity on the protein kinases involved in the regulation of GATA4 phosphorylation. |
|
| DC21426 | NSC654259 | A novel small molecule Wnt signaling inhibitor that targets the cysteine-rich domain of Frizzled, specifically binds to the Wnt binding site on the Frizzled8 cysteine-rich domain with Kd of 2.9 uM, IC50 of 5.7 uM.. |
|
| DC20873 | CCT-031374 hydrobromide | A novel small-molecule Wnt signaling inhibitor that inhibits TCF-dependent transcription with IC50 of 6.1 uM in 7dF3 reporter assay. |
|
| DC21232 | Licogliflozin | A novel sodium glucose transporter type 1 and type 2 (SGLT1/2) inhibitor for the oral treatment of type 2 diabetes.. |
|
| DC23587 | AMG1 | A novel specific CRAC channel inhibitor that blocks function of effector but not regulatory T cells in vitro and attenuates the pogression and severity of EAE in vivo. |
|
| DC21056 | GMI-1271 Featured | A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM. |
|
| DC22863 | FPND | A novel specific ROCK1 kinase inhibitor with IC50 of 11.2 uM, without inhibitory activity against ROCK2. |
|
| DC20372 | Elismetrep | A novel specific TRPM8 channel antagonist for treatment or prevention vasomotor symptoms.. |
|
| DC5893 | SCD1 inhibitor Featured | A novel stearoyl-CoA desaturase1 (SCD1) inhibitor.The compound exhibited robust in vivo activity with dose-dependent desaturation index lowering effects. |
|
| DC22931 | 1Z105 | A novel synthetic, orally bioavailable TLR4/MD2 ligand, significantly reduces the IL-6 secretion by subsequent challenge with LPS at 0.63 uM. |
|
| DC23945 | Pyr10 Featured | Pyr10 is a pyrazole derivative and a selective TRP cation 3 (TRPC3) inhibitor. Pyr10 inhibits Ca2+ influx in carbachol-stimulated TRPC3-transfected HEK293 cells with an IC50 of 0.72 μM (IC50 of 13.08 μM for store operated Ca2+ entry in BRL-2H3 cells). Pyr10 has the ability to distinguish between receptor-operated TRPC3 and native stromal interaction molecule 1 (STIM1)/Orai1 channels[1]. |
|
| DC21298 | Uprifosbuvir | A novel uridine nucleotide analog HCV NS5B polymerase inhibitor for treatment of HCV infection combined with Grazoprevir and Ruzasvir.. |
|
| DC22790 | MELK-T1 hydrochloride | A novel, cell-permeable, potent and selective inhibitor of MELK kinase domain with IC50 of 37 nM. |
|
| DC23430 | THRX-200495 | A novel, dual-acting muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) with pKi of 9.21/9.53 for hM2/M3, pKi of 9.37 for β2-adrenoceptor. |
|
| DC23454 | V0162 | A novel, high affinity and long-acting antagonist of human M3 muscarinic acetylcholine receptor with pKi of 9.03-9.21. |
|
| DC22756 | CHF6001 | A novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM. |
|
| DC24013 | MUT-056399 | A novel, highly potent inhibitor of the FabI enzyme of both Staphylococcus aureus and Escherichia coli. |
|
| DC21389 | NKTR-181 | A novel, long-acting and orally active, selective mu-opioid agonist that displays higher binding affinity (Ki=237 nM) at the MOR than kappa and delta opioid receptors (>100-fold). |
|
| DC24094 | Dofequidar | A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR. |
|
| DC22599 | GLPG-0492 | A novel, orally active, non-steroidal selective androgen receptor modulator (SARM) with in vitro potency of 13 nM. |
|
